Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-muscle-invasive Bladder Cancer
Conditions
Non-muscle-invasive Bladder Cancer
Trial Timeline
May 14, 2018 → Oct 3, 2028
NCT ID
NCT03528694About Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)
Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG) is a phase 3 stage product being developed by AstraZeneca for Non-muscle-invasive Bladder Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03528694. Target conditions include Non-muscle-invasive Bladder Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03528694 | Phase 3 | Active |
Competing Products
2 competing products in Non-muscle-invasive Bladder Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Cretostimogene Grenadenorepvec | CG Oncology | Phase 2 | 49 |
| AU-011 | Aura Biosciences | Phase 1 | 25 |